Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Nouveau Monde Graphite plans to raise capital via stock (SeekingAlpha) +++ NOUVEAU MONDE Aktie -4,89%

ILLUMINA Aktie

 >ILLUMINA Aktienkurs 
110.02 EUR    -0.3%    (Tradegate)
Ask: 110.76 EUR / 136 Stück
Bid: 110.02 EUR / 47 Stück
Tagesumsatz: 40 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
ILLUMINA Aktie über LYNX handeln
>ILLUMINA Performance
1 Woche: -4,2%
1 Monat: +6,3%
3 Monate: +29,3%
6 Monate: +41,9%
1 Jahr: -19,1%
laufendes Jahr: -14,3%
>ILLUMINA Aktie
Name:  ILLUMINA INC. DL-,01
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US4523271090 / 927079
Symbol/ Ticker:  ILU (Frankfurt) / ILMN (NASDAQ)
Kürzel:  FRA:ILU, ETR:ILU, ILU:GR, NASDAQ:ILMN
Index:  S&P500
Webseite:  http://www.illumina.com/
Profil:  Illumina, Inc. operates as a global leader in the ..
>Volltext..
Marktkapitalisierung:  17135.16 Mio. EUR
Unternehmenswert:  18242.62 Mio. EUR
Umsatz:  3652.51 Mio. EUR
EBITDA:  949.57 Mio. EUR
Nettogewinn:  599.23 Mio. EUR
Gewinn je Aktie:  3.82 EUR
Schulden:  2195.77 Mio. EUR
Liquide Mittel:  895.01 Mio. EUR
Operativer Cashflow:  956.39 Mio. EUR
Bargeldquote:  0.65
Umsatzwachstum:  -7.39%
Gewinnwachstum:  -
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  2 Insider verkauften innerhalb der letzten 30 Tage Aktien im Wert von 114.926 USD.
Suchwörter:  ILLUMINA
Letzte Datenerhebung:  18.12.25
>ILLUMINA Kennzahlen
Aktien/ Unternehmen:
Aktien: 152.8 Mio. St.
Frei handelbar: 97.19%
Rückkaufquote: 3.35%
Mitarbeiter: 10370
Umsatz/Mitarb.: 0.36 Mio. EUR
Analysten:
Analystenrating: Neutral
Kursziel: -5.78%
Bewertung:
KGV: 29.31
KGV lG: 27.79
KUV: 4.71
KBV: 8.41
PEG-Ratio: -
EV/EBITDA: 19.21
Rentabilität:
Bruttomarge: 66.79%
Gewinnmarge: 16.41%
Operative Marge: 19.58%
Managementeffizenz:
Gesamtkaprendite: 11.53%
Eigenkaprendite: 31.2%
>ILLUMINA Peer Group

Es sind 599 Aktien bekannt.
 
17.12.25 - 05:01
Insiderhandel: Chief Legal Officer verkauft Aktien von Illumina im Wert von 43957 USD (Insiderkauf)
 
Davies, Scott M. - Vorstand - Tag der Transaktion: 2025-12-12...
16.12.25 - 22:06
Illumina To Webcast Upcoming Investor Conference (PR Newswire)
 
SAN DIEGO, Dec. 16, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that members of its management team will participate at the following investor conference: Upcoming Investor Conference 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 The presentation......
12.12.25 - 17:30
Why Illumina (ILMN) is a Top Momentum Stock for the Long-Term (Zacks)
 
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores....
11.12.25 - 15:18
Illumina and MyOme Strike Collaboration Deal Including Strategic Investment to Support MyOme′s Clinical Trial That Could Save U.S. Healthcare $200 Billion Annually (PR Newswire)
 
Partnership unites Illumina's leading sequencing technology with cutting-edge clinical genomics analyses and AI to advance precision medicine for early detection and prevention. SAN DIEGO and MENLO PARK, Calif., Dec. 11, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) and MyOme, a......
10.12.25 - 00:01
Insiderhandel: SVP, Strategy/Corp Development verkauft Aktien von Illumina im Wert von 70969 USD (Insiderkauf)
 
Wedel, Christensen Jakob - Vorstand - Tag der Transaktion: 2025-12-08...
09.12.25 - 12:01
Zacks.com featured highlights include Illumina, Commercial Metals and Newmont (Zacks)
 
Illumina, Commercial Metals and Newmont stand out as brokers boost ratings amid inflation concerns and shifting economic signals....
03.12.25 - 19:45
Illumina (ILMN) Moves to Strong Buy: Rationale Behind the Upgrade (Zacks)
 
Illumina (ILMN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term....
19.11.25 - 19:48
Pacific Biosciences: Mit Long-Read-Sequenzierung zum Angriff auf Illumina (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
19.11.25 - 17:18
Illumina bekräftigt Wachstumsziele trotz aktueller Herausforderungen/n (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
12.11.25 - 18:03
Illumina whole-genome sequencing provides greater insight into genetic signals behind common diseases--according to Nature study (PR Newswire)
 
Study shows that rare variants captured by Illumina WGS with DRAGEN™ variant calling explain most of the "missing heritability" in complex human diseases and traits, including those related to blood pressure and cholesterol Results demonstrate the advantages of WGS over WES and genotyping......
11.11.25 - 22:09
Illumina To Webcast Upcoming Investor Conference (PR Newswire)
 
SAN DIEGO, Nov. 11, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference: Wolfe Research Healthcare Conference 2025 on November 19, 2025 Fireside chat at 6:20am Pacific Time (9:20am Eastern Time) The......
10.11.25 - 18:18
Illumina® Protein Prep delivers groundbreaking precision in NGS proteomics for more than 40 customers, ranging from academic institutions to large national biobanks (PR Newswire)
 
Following global commercial launch in September, Illumina Protein Prep's "out of the box" solution drives extraordinary accessibility to proteomics for researchers, with over 40,000 samples processed Sydney Mass Spectrometry is the first facility in the wider Asia Pacific region to offer......
10.11.25 - 14:06
Iambic Raises Over $100 Million in an Oversubscribed Round to Advance Its Portfolio of AI-Discovered Therapeutics and Leading Platform Technologies (Business Wire)
 
Support comes from new and existing investors, including life science, technology, growth, and sovereign wealth investors Financing closely follows announcements of Iambic's clinical data for IAM1363 at the ESMO Congress and entry into a clinical collaboration with Jazz Pharmaceuticals SAN DIEGO--(BUSINESS WIRE)--Iambic, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, today announced raising over $100 million in an oversubscribed financing round with balanced support from new and existing investors, including Abingworth, Alexandria Venture Investments, Alumni Ventures, ARK, Ascenta, Catalio, Everbright Biofund, Freeflow Ventures, Illumina Ventures, Mubadala, Pegasus Tech Ventures, Qatar Investment Authority, Regeneron Ventures, Sequoia, Tao Capital Partners, Terra Magnum Capital Partners, Wilson Sonsini Goodrich & Rosati, and others. "We are thrilled to have the support of many outstanding and committed investors...
06.11.25 - 00:01
Insiderhandel: Aufsichtsrat kauft Aktien von Illumina im Wert von 61065 USD (Insiderkauf)
 
Gottlieb, Scott - Aufsichtsrat - Tag der Transaktion: 2025-11-03...
05.11.25 - 23:36
Illumina Says China Removed Ban on Importing DNA Sequencers (Bloomberg)
 
Illumina Inc. said the Chinese government has lifted a ban on the company selling its DNA sequencing machines inside the country....
05.11.25 - 23:19
Illumina Responds to Positive Updates from Chinese Ministry of Commerce (PR Newswire)
 
SAN DIEGO, Nov. 5, 2025 /PRNewswire/ -- The Chinese Ministry of Commerce (MOFCOM) today announced it will lift the export ban on Illumina, Inc. (NASDAQ: ILMN), which had been in place since March 4, 2025. While the ban will be lifted on November 10, Illumina remains on the Unreliable......
05.11.25 - 20:06
Illumina and Grail Veterans Launch Hepta With First Liquid Biopsy-Native AI That Detects Liver Disease With Tissue-Level Biological Insights (Business Wire)
 
The company's transformer model interprets up to one billion DNA fragments in each blood sample, capturing molecular context at a scale hundreds of times greater than leading LLMs and demonstrating strong clinical validation With $6.7 million seed led by Felicis Ventures and Illumina Ventures, Hepta advances liquid biopsy platforms beyond oncology FOSTER CITY, Calif.--(BUSINESS WIRE)--Hepta, a biotechnology company using transformer-based AI to read the cell-free DNA (cfDNA) epigenome and detect organ-specific signals of chronic disease, today emerged from stealth with $6.7 million in seed funding led by Felicis Ventures and Illumina Ventures, with participation from SeaX Ventures, Alumni Ventures, and AME Cloud Ventures. The company also revealed clinical data showing its AI-powered epigenetics platform can identify patients with metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH) with significant fibrosis with a diagnostic AUC of 0.86, cutting false positives threefold compa...
02.11.25 - 16:48
Teradyne, Wayfair, And Illumina Are Among the Top 10 Large-Cap Gainers Last Week (Oct. 27-Oct. 31): Are the Others in Your Portfolio? (Benzinga)
 
Top weekly large-cap gainers included Teradyne, Wayfair, Illumina, Guardant Health, ASE, C.H. Robinson, Lumen, Symbotic, Credo, YPF after strong results. read more...
31.10.25 - 19:25
OPEC+ Balances Oil Risks from Sanctions, Illumina 3Q Beats Estimates | Bloomberg Markets 10/31/2025 (Bloomberg)
 
"Bloomberg Markets" follows the market moves across every global asset class and discusses the biggest issues for Wall Street. Today's guests: Illumina CEO Jacob Thaysen, Bloomberg's Simon Casey and Justin Fox. (Source: Bloomberg)...
31.10.25 - 19:13
′Hopeful′ We′ll Find Long-term Solution On China: Illumina CEO (Bloomberg)
 
Illumina reported revenue growth and raised its financial guidance for the second straight quarter. Illumina CEO Jacob Thaysen acknowledged the ongoing challenges from US–China export restrictions but said Illumina remains committed to the market while maintaining strong performance globally. He discussed the outlook on "Bloomberg Markets" with Scarlet Fu and Bloomberg The Close's co-anchor Katie Greifeld. (Source: Bloomberg)...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Wer lesen kann, der ist niemals einsam. - Prof. Dr. Walter Jens
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!